SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Harriet Tubman

PatientHarriet Tubman
Date of birth1951-03-01
IdentifiersMRN HR-NI005-SYN; SSN (made up) 000-05-3961
Document date2026-05-18
AuthorCarmen Ruiz-Delgado, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Results of ambulatory EEG and sleep studies; four-week headache check. [S]

History of Present Illness

Mrs. Tubman returns for her test results and a headache check four weeks after starting candesartan 8 mg. Four of her typical spells were captured during the ambulatory EEG, and the overnight and daytime sleep studies are complete. Her sleep spells continue several times a day. Her headache diary shows fewer headache days than before, though still more than she would like, and she has used acetaminophen about once a week, with no ibuprofen since the first visit. She has had no dizziness on standing, swelling, or cough on candesartan. [S]

ElementDetail
Testing completedAmbulatory EEG with video, overnight polysomnography, and multiple sleep latency test
Sleep spellsUnchanged, several a day
Headache diaryFewer headache days since starting candesartan; partial response
Acute medicineAcetaminophen about once a week; no ibuprofen
Candesartan toleranceNo dizziness, swelling, or cough

Review of Systems

SystemResultFinding
NeurologicalPositiveSleep spells several times a day; fewer headaches; no weakness or numbness
CardiovascularNegativeNo palpitations, chest pain, or light-headedness on standing
RespiratoryNegativeNo snoring or witnessed pauses in breathing reported; no cough
PsychiatricNegativeMood steady; no anxiety about the results

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Ibuprofen 200 mg oral tablet, two tablets by mouth most days (self-directed, over the counter)Two tablets by mouth most daysOral route2025-09-01 to 2026-04-06stoppedS
Acetaminophen 500 mg oral tablet, two tablets by mouth as needed for headache, no more than 2 days a weekTwo tablets by mouth as needed, at most 2 days a weekOral route2026-04-06activeS
Candesartan 8 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-04-20 to 2026-05-18completedS
Candesartan 16 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-18activeS
Modafinil 100 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route2026-05-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-18Body height152cmS
2026-05-18Body weight51.5kgS
2026-05-18Body mass index (BMI) [Ratio]22.3kg/m2S
2026-05-18Systolic blood pressure132mm[Hg]S
2026-05-18Diastolic blood pressure80mm[Hg]S
2026-05-18Heart rate72/minS
2026-05-18Respiratory rate14/minS
2026-05-18Body temperature36.6CelS
2026-05-18Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-18Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-05-18Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-05-18Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.59-1.04 mg/dLNormalS
2026-05-18Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M67mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-05-18Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-05-18PROMIS sleep related impairment - version 1.0 Tscore67{score}S

Physical Exam

Vital signs recorded on 2026-05-18; see the Vital Signs section. [S]

SystemFinding
GeneralAlert; no spell during the visit
CardiovascularRegular rhythm; no edema
NeurologicalNonfocal; gait normal

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent sudden sleep episodes since an adolescent traumatic brain injury; narcolepsy without cataplexy due to a medical condition, provisional; historical cause retrospectively disputedactiveprovisional G47.429S — Synthetic diagnosis from the modern sleep testing; it echoes, but does not confirm, the R proposal of post-traumatic narcolepsy.
Chronic post-traumatic headache since an adolescent head injuryactiveconfirmed G44.329S — Synthetic modern coding of the documented lifelong headaches.
Medication-overuse headache from near-daily ibuprofen, resolved after withdrawalresolvedconfirmed G44.40S — Synthetic finding; resolved by the three-month review.
Sequelae of a traumatic brain injury in adolescence, a skull fracture by historical accountactiveconfirmed S06.9XASS — Synthetic modern coding of the documented injury; the MRI findings in the episode are synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationAmbulatory EEG with videoWhen routine EEG is not diagnosticCompleted todayReviewed today: four typical spells captured, each at sleep onset with no ictal pattern
ExaminationOvernight polysomnography and multiple sleep latency testFor excessive daytime sleepinessCompleted todayReviewed today: apnea-hypopnea index 4; mean sleep latency 4.5 minutes with two sleep-onset REM periods
Medication safetyAntiseizure medicineOnly if spells prove epilepticNot indicatedSpells are sleep attacks; no antiseizure medicine
SurveyPROMIS sleep-related impairmentAt baseline and after treatmentCompleted todayT-score 67, little changed from 68 before treatment
Medication safetyModafinil: blood pressure and heart rateBefore starting and at follow-upCompleted todayBaseline 132/80 mmHg, pulse 72; started today at 100 mg for an older adult
LaboratoryBasic metabolic panel (potassium and creatinine) on candesartanBefore starting and a few weeks after; then periodicallyCompleted todayFour weeks after starting: potassium 4.6, creatinine 0.90, eGFR 67, sodium and glucose normal
ExaminationBlood pressure, heart rate, and weightEvery visitCompleted today132/80 mmHg, pulse 72, weight 51.5 kg
Self-managementHeadache diary (headache days and acute-medicine days)DailyCompleted todayReviewed; fewer headache days since starting candesartan
Medication safetyAcute headache medicine on no more than 2 days a weekEvery visitCompleted todayAcetaminophen about once a week; no ibuprofen
SurveyHeadache days per three months2 to 3 months after starting preventionDueAt the three-month review
Self-managementSafety advice for sudden sleep episodesEvery visitCompleted todayReviewed; scheduled naps added
SurveyDepression screen (PHQ-9)At baseline and at follow-upDueAt the three-month review

Goal progress:

Guideline basis: Evidence-based guideline: Management of an unprovoked first seizure in adults (Krumholz A, et al. Neurology 2015;84(16):1705-1713) (2015); Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline (Maski K, et al. J Clin Sleep Med 2021;17(9):1881-1893) (2021); The International Classification of Headache Disorders, 3rd edition (Cephalalgia 2018;38(1):1-211) (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (Ailani J, et al. Headache 2021;61(7):1021-1039) (2021)

Follow-up: Three-month sleepiness and headache review with potassium and creatinine, PROMIS score, headache-day count, and PHQ-9. Next scheduled visit 2026-08-17: three-month sleepiness and headache review. [S]